MedTrace Logo

Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis

NCT07037823 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 328

Last updated 2025-06-26

No results posted yet for this study

Summary

This study was designed to investigate the effectiveness of a combined strategy utilizing disease-modifying therapy and the modified Yishen Daluo Yin formula for relapsing-remitting multiple sclerosis (RRMS) through a prospective, multicenter, observational comparative study.

Conditions

  • RRMS

Interventions

OTHER

Modified Yishen Daluo Yin formula

The specific application of the modified Yishen Daluo Yin formula, including the starting point, dosage, and duration of treatment, should be determined based on medical advice, the patient's condition, and their individual preferences.

Sponsors & Collaborators

  • The Second Hospital of Hebei Medical University

    collaborator OTHER

  • First Affiliated Hospital of Jinan University

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Ying Gao

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-10-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07037823 on ClinicalTrials.gov